2026 BMW M3 Pricing Leaked; Up $1700 from Last Year
A leaked internal memo shows price increases of $1700 across the board, moving the M3 to $79,575, the Competition to $83,775, and the Competition xDrive to $88,875.
Car and Driver reached out to BMW to confirm the authenticity of the document and will update this story when we hear back.
The floor for BMW M3 ownership is rising once again. An internal memo from BMW leaked to the forum Bimmerpost, and first reported by Motor1, reveals that the 2026 M3 price is jumping $1700 from last year's car.
BMW
Unfortunately, the price hike isn't just for the standard M3, at hits evenly across the board. The increase moves the standard M3 up to $79,575, the rear-drive Competition up to $83,775, and the AWD Competition xDrive up to $88,875.
The actual model offerings from BMW continue unchanged. While it's the least powerful, the base M3 remains the only model available with a three-pedal setup—and still sends a healthy 473 horsepower and 406 pound-feet of torque to the rear wheels. The Competition models come in standard rear-drive, but the optional AWD xDrive setup is back. Competition models spit out 503 horses and 479 pound-feet of torque, though the downside of the more powerful models is that they're only offered with an eight-speed automatic transmission.
According to the memo, production of the 2026 model is scheduled to start in July, and the increased pricing has already gone into effect for cars ordered now. Car and Driver reached out to BMW to confirm the veracity of the document and will update this story when we hear back.
Jack Fitzgerald
Associate News Editor
Jack Fitzgerald's love for cars stems from his as yet unshakable addiction to Formula 1.
After a brief stint as a detailer for a local dealership group in college, he knew he needed a more permanent way to drive all the new cars he couldn't afford and decided to pursue a career in auto writing. By hounding his college professors at the University of Wisconsin-Milwaukee, he was able to travel Wisconsin seeking out stories in the auto world before landing his dream job at Car and Driver. His new goal is to delay the inevitable demise of his 2010 Volkswagen Golf. Read full bio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
ProSieben investor General Atlantic opts for Czech PPF offer, shuns MFE, sources say
MUNICH (Reuters) -Financial investor General Atlantic has tendered its 2.4% stake in German media group ProSiebenSat.1 to Czech investment company PPF, two people familiar with the matter told Reuters on Tuesday. By taking PPF's cash offer of 7 euros ($8.17) per share for ProSieben, General Atlantic is going against the endorsement of ProSieben's management for a higher rival offer by MFE-MediaForEurope, which is partly paid in MFE shares, indicating that MFE faces some difficulties in its bid for control over ProSieben. General Atlantic, PPF and ProSieben declined to comment. MFE did not immediately respond to a request for comment. ($1 = 0.8567 euros)
Forbes
23 minutes ago
- Forbes
How Collaborations Are Helping London Biotechs Find A Route To Market
Partnerships and collaborations provide an important means for life sciences and healthtech startups to validate their technologies, secure financial backing and navigate a route to market. London, with its concentration of teaching hospitals, universities and research institutions, all sitting in close proximity to local and global VC firm headquarters, may be well placed to nurture the next generation of health innovators. The challenge is to make the most of the existing ecosystem. When it comes down to raising VC finance, Britain's healthtech and life sciences startups are doing rather well. Witness the last set of quarterly figures published by HSBC Innovation Banking and Dealroom. According to the data, healthtech businesses raised $1.8 billion in the first three months of this year, the largest sum since the second quarter of 2021. More than half the money raised went to businesses developing AI solutions. And the government is playing its part in boosting the sector. For instance, earlier this year, Finance Minister Rachel Reeves announced a £29 billion boost for Britain's National Health Service, with £10 billion of that earmarked for investment in new technologies. To underline that point, an initiative dubbed the Innovator Passport will allow digital solutions tested in one health organisation to be rolled out across others without further checks. This could be hugely important in the U.K., where the national health system is administered locally through trusts that tend to work independently of each other. It's all part of a 'Modern Industrial Strategy' plan aimed at helping the U.K. to become a 'world leader' in health-related technologies. All well and good, but small life sciences and healthtech companies still face the challenge of proving the efficacy of their solutions and also demonstrating how they can be integrated into existing clinical systems. The Partnership Solution One way forward for technology-led startups is to partner with bigger players that can provide resources and access to markets that might otherwise be out of reach. David Roblin is CEO and co-founder of Relation Therapeutics, a company that is collaborating with pharmaceutical giant GSK on developing treatments for osteoarthritis and fibrosis. As he explains, the company was established to bring together people from disparate scientific disciplines and working backgrounds, with the aim of developing an interdisciplinary approach to drug discovery. In practical terms this means that biologists working in the field of genomics, cells and tissues are working alongside experts in machine learning and R&D. As Roblin sees it, the collaboration is helping partner GSK to develop treatments for the targeted illnesses more quickly than would otherwise be the case. "Trying to innovate in a big company with established processes is quite a challenge,' says Roblin. "GSK had all the elements but they didn't have the blank sheet of paper to bring the technologies to bear at the right time and at the right pace.' In return, he says, the relationship with GSK has enhanced Relation Therapeutics' profile and credibility. Indeed, Roblin says the deal played an important part in helping his business secure a $65 million Seed round. "The collaboration was quite important in closing the seed round. GSK brought cash, validation and they also brought ideas and a deep understanding of the diseases,' he says, Every partnership is different in terms of the benefits it delivers. Pangaea Data is a U.K.-based company that has developed a platform that can help clinicians identify hard-to-diagnose diseases. This is achieved by using AI to analyse patient symptoms mapped against models created using existing clinical guidelines. The company says the platform has been used to accelerate diagnoses across 42 conditions. Last month, Pangaea Data announced a partnership with AstraZeneca-owned Alexion Pharmaceuticals. Under the arrangement, Pangaea will configure its platform to detect Hypophosphatisia (HPP), a bone-softening genetic disorder. So what does the collaboration deliver? Well as co-founder Vibhor Gupta acknowledges, once a technology solution has been developed, the challenge is to find a pathway through which the product can be introduced to health systems. "There is the question of who will pay for it,' he says. 'That's why the partnership with Alexion is important. They have a treatment for HPP. We can use the partnership to allow health systems to identify patients who are hiding in plain sight. In other words, there is a symbiosis. Alexion has a treatment for the condition. Pangaea provides a means to find patients who are currently undiagnosed and thus slipping through the treatment net. As Gupta explains, pharmaceutical companies are solutions-driven. 'They don't necessarily have all the data they need - health systems have that - but what they do possess is the motivation to close care gaps and get patients to the right treatment or trials,' he says.' A Collaborative Ecosystem The benefits of collaboration extend far beyond commercial relationships between two companies. For instance, there may also be opportunities for life sciences and health-tech startups to work with universities and research institutes, sharing labs, resources and expertise. This kind of collaboration can be arranged and orchestrated across countries and continents if need be, but it can be - to say the least - helpful if potential partners are situated within walking distance of each other and perhaps meeting regularly at the same events. That's the view of Mike Wiseman, Head of Campuses, at business space provider British Land. Included in his company's portfolio is Regents Place, a mix of labs and office spaces situated on London's Euston Road, an area increasingly referred to as the Knowledge Quarter. As Wiseman points out, the district is home to Meta, Google and Deepmind, along with the Francis Crick medical research institute, The Alan Turing Institute (data and AI) , the University of London and a host of science and technology companies. British Land is positioning Regents Place as a campus for AI and health technology. 'We have a community of likeminded people. Some of the most exciting advances in science are at the intersection of different disciplines and we can facilitate that through spaces and events," says Wiseman. To that end, the company has signed a memo of understanding to work with the University of London on events and there is also an arrangement with the Crick Institute that allows startups from Regents to share lab facilities. Wiseman says this bodes well for the future. London still lags Boston as a health tech and life sciences hub but the building blocks are in place. As he points out, in addition to possible collaborators, regulators and investors are also close at hand. 'You also have access to patients through the NHS and the private clinics of Harley Street. There are very few places like this," he adds. Another complex, Triton Square. is due to open shortly. There is a bigger picture. London is part of the so-called Golden Triangle that also includes Oxford and Cambridge and there is collaboration not just within but between cities. However, startups are likely to benefit from being in proximity to sources of support.
Condé Nast Traveler
an hour ago
- Condé Nast Traveler
Inside the Leather Workshops of Andalusia
Menacho opened his workshop in the whitewashed village of Castilblanco de los Arroyos, a 45-minute drive north of Seville, a decade ago—but had never planned to work with leather. A keen equestrian, he wanted to become a riding instructor but failed the entrance exam. 'The following week they called me to see if I wanted to join the saddlery course instead,' he says. 'I said yes because I'd always enjoyed working with my hands. I learned cutting and stitching, how to differentiate between leather types, and how to make basic riding bags,' he says. It was through making saddles, tack, and other equestrian items, that he acquired the techniques that would make him a leading leathermaker in Spain—and across the fashion world. But the craft, and the ancient artisanal methods he follows, holds a deep significance for Menacho. Leatherwork in Andalusia dates back as far as the Islamic period, when cities like Córdoba became hubs for the trade. 'For me, it's a way of life and a symbol of identity,' he says. This history, and the region's deep connection with horses—as seen through its rich culture of agriculture and equestrianism—has led generations of Sevillian leather workers to hone and evolve the craft. Sacred art related to Seville's Semana Santa Easter festivities is at the root of many artisans' designs, while others are inspired by the city's rich mix of Moorish, Gothic, Mudejar, Renaissance and Baroque architecture. But artisanal work is hard work, and a number of craftspeople are beginning to rely more on machinery than the traditional methods to create their products. Younger generations, meanwhile, are moving away from the professions of their parents to embark on more modern careers. Both are developments that Menacho and many of his peers worry will not only dilute the quality of the product, but this intrinsic part of Andalusian life more deeply, too. 'The work of an artisan is culture, art, and history, but it can also be the future,' he says. 'I try to show people the real value of artisanal work so that we don't lose it.' Menacho, whose workshop is almost entirely free of machinery, does 90% of his work by hand Cristina Gómez Ruiz Techniques done by hand by artisans like Menacho distinguish, in their book, their work from industrial product Cristina Gómez Ruiz Menacho's own leather craft involves chiseling and scoring, die-cutting and stitching, embossing and gilding. He treats his leathers the traditional way with vegetable dyes in oak barrels, a process that can take between six and twelve months. His workshop is practically free of machinery, and 90% of the work he does is by hand, often using techniques that date back centuries, something that Menacho feels distinguishes an artisanal product from something industrial. 'The old, traditional methods are the ones that really work. Some of them date back 500 or 800 years. They're based on time, rhythm, and knowledge of materials,' he says.
